Argus analyst Stephen Biggar initiated TESARO with a Buy and a $210 price target saying he expects it to continue to advance its diverse pipeline of oncology drugs and to become a fully integrated commercial company. Biggar likes TESARO for its presence in several emerging areas of oncology, including PARP inhibitors and immuno-oncology products that promote the normal function of checkpoint regulators, such as PD-1, TIM-3 and LAG-3, and thus help the immune system respond effectively to tumors. The analyst expects larger biopharmaceutical companies to show acquisition interest in TESARO given its progress in drug development and strong position in its target markets.